MEDICLIN AG (MED.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:MED - DE0006595101 - Common Stock
3.78 EUR
0 (0%)
Taking everything into account, MED scores 6 out of 10 in our fundamental rating. MED was compared to 29 industry peers in the Health Care Providers & Services industry. While MED has a great profitability rating, there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on MED.
1. Profitability
1.1 Basic Checks
In the past year MED was profitable.
MED had a positive operating cash flow in the past year.
In multiple years MED reported negative net income over the last 5 years.
In the past 5 years MED always reported a positive cash flow from operatings.
1.2 Ratios
With a decent Return On Assets value of 3.85%, MED is doing good in the industry, outperforming 72.41% of the companies in the same industry.
MED has a Return On Equity of 14.15%. This is in the better half of the industry: MED outperforms 68.97% of its industry peers.
The Return On Invested Capital of MED (7.06%) is better than 68.97% of its industry peers.
MED had an Average Return On Invested Capital over the past 3 years of 3.46%. This is below the industry average of 6.67%.
The last Return On Invested Capital (7.06%) for MED is above the 3 year average (3.46%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.85% | ||
| ROE | 14.15% | ||
| ROIC | 7.06% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
1.3 Margins
Looking at the Profit Margin, with a value of 4.40%, MED is in the better half of the industry, outperforming 72.41% of the companies in the same industry.
MED's Profit Margin has improved in the last couple of years.
MED's Operating Margin of 8.52% is fine compared to the rest of the industry. MED outperforms 72.41% of its industry peers.
MED's Operating Margin has improved in the last couple of years.
MED's Gross Margin of 84.08% is amongst the best of the industry. MED outperforms 82.76% of its industry peers.
In the last couple of years the Gross Margin of MED has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.52% | ||
| PM (TTM) | 4.4% | ||
| GM | 84.08% |
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MED is still creating some value.
Compared to 1 year ago, MED has about the same amount of shares outstanding.
The number of shares outstanding for MED remains at a similar level compared to 5 years ago.
The debt/assets ratio for MED has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.60, we must say that MED is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.60, MED is doing worse than 62.07% of the companies in the same industry.
MED has a debt to FCF ratio of 9.63. This is a negative value and a sign of low solvency as MED would need 9.63 years to pay back of all of its debts.
With a Debt to FCF ratio value of 9.63, MED perfoms like the industry average, outperforming 48.28% of the companies in the same industry.
A Debt/Equity ratio of 1.69 is on the high side and indicates that MED has dependencies on debt financing.
MED has a Debt to Equity ratio of 1.69. This is in the lower half of the industry: MED underperforms 65.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.69 | ||
| Debt/FCF | 9.63 | ||
| Altman-Z | 1.6 |
ROIC/WACC1.47
WACC4.81%
2.3 Liquidity
A Current Ratio of 1.93 indicates that MED should not have too much problems paying its short term obligations.
MED's Current ratio of 1.93 is amongst the best of the industry. MED outperforms 89.66% of its industry peers.
A Quick Ratio of 1.89 indicates that MED should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.89, MED belongs to the top of the industry, outperforming 93.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.89 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 414.18% over the past year.
Measured over the past years, MED shows a very strong growth in Earnings Per Share. The EPS has been growing by 20.79% on average per year.
Looking at the last year, MED shows a small growth in Revenue. The Revenue has grown by 3.40% in the last year.
The Revenue has been growing slightly by 2.19% on average over the past years.
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%
3.2 Future
MED is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.09% yearly.
MED is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.42% yearly.
EPS Next Y62.2%
EPS Next 2Y28.31%
EPS Next 3Y20.09%
EPS Next 5YN/A
Revenue Next Year5.05%
Revenue Next 2Y3.88%
Revenue Next 3Y3.42%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
MED is valuated cheaply with a Price/Earnings ratio of 5.11.
Based on the Price/Earnings ratio, MED is valued cheaper than 100.00% of the companies in the same industry.
MED is valuated cheaply when we compare the Price/Earnings ratio to 26.49, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 5.54 indicates a rather cheap valuation of MED.
MED's Price/Forward Earnings ratio is rather cheap when compared to the industry. MED is cheaper than 100.00% of the companies in the same industry.
MED is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.69, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.11 | ||
| Fwd PE | 5.54 |
4.2 Price Multiples
MED's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MED is cheaper than 96.55% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, MED is valued cheaper than 86.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.86 | ||
| EV/EBITDA | 2.91 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MED has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as MED's earnings are expected to grow with 20.09% in the coming years.
PEG (NY)0.08
PEG (5Y)0.25
EPS Next 2Y28.31%
EPS Next 3Y20.09%
5. Dividend
5.1 Amount
MED has a Yearly Dividend Yield of 1.06%.
MED's Dividend Yield is comparable with the industry average which is at 2.40.
With a Dividend Yield of 1.06, MED pays less dividend than the S&P500 average, which is at 2.31.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.06% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y28.31%
EPS Next 3Y20.09%
FRA:MED (12/5/2025, 7:00:00 PM)
3.78
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners1.17%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap179.55M
Revenue(TTM)797.34M
Net Income(TTM)35.05M
Analysts83.33
Price Target5.87 (55.29%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.06% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)22.34%
PT rev (3m)22.34%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)6.4%
EPS NY rev (3m)6.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.48%
Revenue NY rev (3m)0.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.11 | ||
| Fwd PE | 5.54 | ||
| P/S | 0.23 | ||
| P/FCF | 3.86 | ||
| P/OCF | 1.86 | ||
| P/B | 0.73 | ||
| P/tB | 0.8 | ||
| EV/EBITDA | 2.91 |
EPS(TTM)0.74
EY19.58%
EPS(NY)0.68
Fwd EY18.04%
FCF(TTM)0.98
FCFY25.9%
OCF(TTM)2.04
OCFY53.84%
SpS16.79
BVpS5.21
TBVpS4.7
PEG (NY)0.08
PEG (5Y)0.25
Graham Number9.32
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.85% | ||
| ROE | 14.15% | ||
| ROCE | 9.1% | ||
| ROIC | 7.06% | ||
| ROICexc | 9.61% | ||
| ROICexgc | 10.05% | ||
| OM | 8.52% | ||
| PM (TTM) | 4.4% | ||
| GM | 84.08% | ||
| FCFM | 5.83% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
ROICexc(3y)4.47%
ROICexc(5y)3.03%
ROICexgc(3y)4.72%
ROICexgc(5y)3.22%
ROCE(3y)4.46%
ROCE(5y)3.03%
ROICexgc growth 3Y64.29%
ROICexgc growth 5Y26.18%
ROICexc growth 3Y68.25%
ROICexc growth 5Y27.23%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
F-Score8
Asset Turnover0.88
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.69 | ||
| Debt/FCF | 9.63 | ||
| Debt/EBITDA | 3.49 | ||
| Cap/Depr | 96.09% | ||
| Cap/Sales | 6.29% | ||
| Interest Coverage | 3.18 | ||
| Cash Conversion | 80.47% | ||
| Profit Quality | 132.66% | ||
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.89 | ||
| Altman-Z | 1.6 |
F-Score8
WACC4.81%
ROIC/WACC1.47
Cap/Depr(3y)56.34%
Cap/Depr(5y)45.08%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
EPS Next Y62.2%
EPS Next 2Y28.31%
EPS Next 3Y20.09%
EPS Next 5YN/A
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%
Revenue Next Year5.05%
Revenue Next 2Y3.88%
Revenue Next 3Y3.42%
Revenue Next 5YN/A
EBIT growth 1Y281.51%
EBIT growth 3Y73.21%
EBIT growth 5Y21.8%
EBIT Next Year136%
EBIT Next 3Y33.79%
EBIT Next 5YN/A
FCF growth 1Y196.83%
FCF growth 3Y-17.96%
FCF growth 5Y7.78%
OCF growth 1Y96.85%
OCF growth 3Y-0.57%
OCF growth 5Y2.97%
MEDICLIN AG / MED.DE FAQ
What is the ChartMill fundamental rating of MEDICLIN AG (MED.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to MED.DE.
What is the valuation status for MED stock?
ChartMill assigns a valuation rating of 9 / 10 to MEDICLIN AG (MED.DE). This can be considered as Undervalued.
What is the profitability of MED stock?
MEDICLIN AG (MED.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for MED stock?
The Price/Earnings (PE) ratio for MEDICLIN AG (MED.DE) is 5.11 and the Price/Book (PB) ratio is 0.73.
What is the earnings growth outlook for MEDICLIN AG?
The Earnings per Share (EPS) of MEDICLIN AG (MED.DE) is expected to grow by 62.2% in the next year.